Finally, by demonstrating overexpression of Cmip and Gbp2 in the hepatocytes of patients with NAFLD, we suggest a reasonable possibility that both proteins could be effective targets for NAFLD prevention and treatment. Here, CMIP is linked to metabolic dysfunction-associated steatotic liver disease.